 |
Px PulseAuthor: Px Pulse
Px Pulse explores vital topics confronting the field of HIV prevention research. Our monthly podcast will deepen your knowledge and help you check the pulse of this fast-paced field and the urgent challenges still ahead. Tune in for interviews, first-person accounts and robust discussion from advocates, researchers, policy-makers and community stakeholders as they take on critical issues facing HIV prevention research today. Language: en Genres: Health & Fitness, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
S5 Ep19: Up Next: A monthly pill for PrEP?
Episode 19
Friday, 15 August, 2025
The drug maker Merck recently announced its plans to start two new trials, known as the EXPrESSIVE program, testing a monthly pill for PrEP. A once-a-month PrEP pill holds great potential for the field. Even with daily pills, a monthly ring, or long acting injectables such as cabotegravir and recently FDA-approved lenacapavir, there’ll be people who can’t find what they really need for prevention. For advocates who follow prevention, there’s a lot to know about these trials, and powerful lessons to learn about Good Participatory Practice (GPP) and impactful involvement of stakeholders—especially community—in research. GPP has been a cornerstone of the process of design and protocol development for the EXPrESSIVE trials, and it doesn’t stop there. This episode features Merck Senior Principal Scientist Rebeca Plank and AVAC’s Regional Manager for Research Engagement Grace Kumwenda. They explain why a monthly pill could be so important to HIV prevention and how GPP is shaping the design and rollout of the trials.
